Aberrant sialylation is causally linked to therapy resistance in cancer [55], and ST6GAL1 has been identified as a mediator of treatment resistance in several tumour types, including pancreatic cancer [78], colorectal cancer [73,79], leukaemia [80,81], and gastric cancer [72]. Here, ST6GAL1 is linked to gastric cancer.